The role of cytokine system RANKL/RANK/OPG in the regulation of bone metabolism

D. S Aganov , V. V Tyrenko , E. N Tsygan , M. M Toporkov , S. G Bologov

Genes & Cells ›› 2014, Vol. 9 ›› Issue (4) : 50 -52.

PDF
Genes & Cells ›› 2014, Vol. 9 ›› Issue (4) : 50 -52. DOI: 10.23868/gc120378
Articles
review-article

The role of cytokine system RANKL/RANK/OPG in the regulation of bone metabolism

Author information +
History +
PDF

Abstract

The review describes the modern data concerning the cellular and molecular mechanisms of mineral metabolism disturbance in bone tissue. Cytokine system consisting of receptor activator of nuclear factor к-b, its ligand and osteoprotegerin (RANKL/RANK/OPG) has a key role in understanding of bone remodeling regulation. We discuss a significance of the cytokine system in osteoblasto- and osteoclastogenesis. Molecular processes of histogenesis and bone resorption have been analyzed.

Keywords

osteoporosis / cytokine system RANKL/RANK/ OPG / bone tissue / mineral metabolism / remodeling / osteoblast / osteoclast

Cite this article

Download citation ▾
D. S Aganov, V. V Tyrenko, E. N Tsygan, M. M Toporkov, S. G Bologov. The role of cytokine system RANKL/RANK/OPG in the regulation of bone metabolism. Genes & Cells, 2014, 9(4): 50-52 DOI:10.23868/gc120378

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Franklin J., Englund M., Ingvarsson T. The association between hip fracture and hip osteoarthritis: A case-control study. BMC Musculoskelet. Disord. 2010; 11(1): 274.

[2]

Торопцова Н.В., Михайлов Е.Е., Беневоленская Л.И. Проблема остеопороза в современном мире. Росс. мед. журн. 2005; 13(24): 1582-5.

[3]

Cooper C., Atkinson E.J., Jacobsen S.J. et al. Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 1993; 137(9): 1001-5.

[4]

Bliuc D., Nguyen N.D., Milch V.E. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301(5): 513-21.

[5]

Olszynski W.P., Shawn Davison K., Adachi J.D. et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin. Ther. 2004; 26(1): 15-28.

[6]

Cameron D.A. The biochemistry and physiology of bone. The ultrastructure of bone 2012; 1: 191-236.

[7]

Riggs B.L. The pathogenesis of involutional osteoporosis. Seventh Bath Conference on Osteoporosis, UK. Osteoporosis Int. 2000; 11 Suppl 1: 1-20

[8]

Аничков Н.М., Дергунов А.В., Цыган В.Н. и др. Патофизиология обмена веществ. Санкт-Петербург: СпецЛит; 2013.

[9]

Papaioannou A., Morin S., Cheung A.M. et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can. Med. Assoc. J. 2010; 182(17): 1864-73.

[10]

Reddi A.H., Roodman D., Freeman C. et al. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J. Bone Miner. Res. 2003; 18 (2): 190-4.

[11]

Raska O., Bernaskova K. Bone metabolism: a note on the significance of mouse models. Physiol. Res. 2009; 58: 459-71.

[12]

Belanger L., Leonard F., Migicovsky B. Histochemical evidence of proteolysis in bone: the influence of parathormone. J. Histochem. Cytochem. 1963; 11(6): 734-7.

[13]

Цыган Е.Н., Деев Р.В. Морфофункциональные основы остеопороза. Санкт-Петербург: ВМедА; 2007.

[14]

Bianco P., Fisher L.W., Young M.F. et al. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif. Tissue Int. 1991; 49(6): 421-6.

[15]

Walsh M.C., Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Inflammation 2014; 5: 511.

[16]

Lacey D.L., Dunstan C.R., Kelley M. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89 (2): 309-19.

[17]

Tsuda E., Goto M., Mochizuki S.I. et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Bioph. Res. Co. 1997; 234(1): 137-42.

[18]

Lacey D.L., Timms E., Tan H.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93(2): 165-76.

[19]

Yasuda H.,Shima N., Nakagawa N.et al.Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS USA. 1998; 95(7): 3597-602.

[20]

Simonet W.S., Lacey D.L., Dunstan C.R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89(2): 309-19.

[21]

Kadono Y., Okada F., Perchonock C. et al. Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep. 2005; 6(2): 171-6.

[22]

Wada T, Nakashima T, Oliveira-Dos-Santos A. et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat. Med. 2005; 11(4): 394-9.

[23]

Wang X.F., Zhang Y.K., Yu Z.S., Zhou J.L. The role of the serum RANKL/OPG ratio in the healing of intertrochanteric fractures in elderly patients. Mol. Med. Rep. 2013; 7(4): 1169-72.

[24]

Wong B., Josien R., Lee Y. et al. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 1998; 273(43): 28355-9.

[25]

Жоголев К.Д, Никитин В.Ю, Цыган Е.Н. и др. Регуляция остеогенеза и иммуногенеза репаративных процессов. Санкт-Петербург: ВМедА, 2003.

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

167

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/